Physician profile
Reagan Cox
NPI 1225863699
$1,493.55
in general payments reported to CMS, 2019-2025
33 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $30.00 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $229.90 | 2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $174.45 | 2025 | Erleada, Rybrevant, Darzalex |
| Beone Medicines USA, INC. | $115.57 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $72.78 | 2025 | Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $69.83 | 2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $67.81 | 2025 | |
| Incyte Corporation | $62.35 | 2025 | Monjuvi, Zynyz, Jakafi |
| Pfizer INC. | $48.90 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.88 | 2025 | |
| Glaxosmithkline, LLC. | $44.86 | 2025 | Blenrep, Ojjaara |
| Array Biopharma INC | $42.42 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Merck Sharp & Dohme LLC | $42.11 | 2025 | Keytruda, Keytruda Qlex |
| Abbvie INC. | $40.19 | 2025 | |
| Gilead Sciences, INC. | $39.20 | 2025 | Trodelvy |
| Agios Pharmaceuticals, INC. | $39.16 | 2025 | Pyrukynd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $34.90 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $31.14 | 2025 | Libtayo |
| Eisai INC. | $28.94 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.23 | 2025 | Ultomiris |
| Recordati_rare_diseases_inc. | $21.06 | 2025 | Enjaymo |
| Coherus Oncology, INC. | $20.55 | 2025 | Loqtorzi |
| Pharmaessentia USA Corporation | $18.83 | 2025 | Besremi |
| Kite Pharma, INC. | $18.42 | 2025 | Yescarta |
| Acrotech Biopharma INC. | $17.95 | 2025 | Beleodaq |
| Karyopharm Therapeutics INC. | $17.82 | 2025 | Xpovio |
| Emd Serono, INC. | $17.52 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.33 | 2025 | |
| Genmab U.S., INC. | $16.22 | 2024 | Epkinly |
| Dendreon Pharmaceuticals LLC | $14.93 | 2025 | Provenge |
| Geron Corporation | $14.55 | 2025 | Rytelo |
| Sobi, INC | $13.73 | 2025 | |
| Exelixis INC. | $13.62 | 2025 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.